Life Sciences Archive » December, 2025

Life Sciences - December, 2025

182 articles

• The Biggest Rulings From A Busy Year At The 1st Circ.
• ITC Clears Toy Gun Imports, Will Review Smart Rings, Vapes
• Eli Lilly Workers Say Justices Needn't Mull Collective Standard
• InnovAge Investors Get Final OK For $27M Deal, Atty Fees
• Top Trade Secrets Decisions Of 2025
• Top Product Liability Cases Of 2025
• UC Researchers Near Reinstating $7B In DOE Grants
• SF Must Reinstate Worker Fired For Violating COVID Vax Rule
• AstraZeneca Can't Block Colo. Law Over Drug Discount Rules
• HHS Proposes Hospital Ban On Gender Care For Minors
• Agita Over Piglets At Party Got Pharma Exec Axed, Suit Says
• 2025 Legal Milestones That Will Shape Psychedelics Sector
• Trump Orders Loosening Of Federal Restrictions On Marijuana
• Nature Photography Makes Me A Better Lawyer
• Sterne Kessler Draws Scolding, But No Sanctions Midtrial
• Shutdown Deal Bars Federal Firings Until Feb., Judge Says
• Conn. Zantac Injury Bellwether Trials Set To Begin In 2028
• Great American Says Cryo Unit Co. Hid Facts In Getting Policy
• What Defense Teams Must Know About PFAS Testing Methods
• Law School's Missed Lessons: Practical Problem Solving
• Doctors Not Harmed By CDC's Vaccine Guidance, Feds Say
• Intellectual Property Challenges In AI-Driven Drug Discovery
• Adderall Telehealth Startup Indicted After CEO's Conviction
• Reel Justice: 'The Mastermind' And Juror Decision-Making
• The Spiciest Quotes From Massachusetts Courts In 2025
• Dana-Farber To Pay $15M To Resolve Fraud Allegations
• Ex-NIAID Director Claims Retaliation in Trump Admin Suit
• Samsung Wants ITC To Consider Oura Smart Ring IP Fight
• PE-Backed Medline Prices Long-Awaited $6.3B IPO
• Ultrahuman Loses Bids To Halt ITC Order In Oura Patent Case
• DOD To Reevaluate Discharges Over COVID Vax Refusal
• Vax Skeptics Cite High Court In New Challenge To NY Mandate
• Learning From 2025 FCA Trends Targeting PE In Healthcare
• Software Patents May Face New Eligibility Scrutiny
• PTAB Cuts X-Ray Patent Claims After Fed. Circ. Remand
• Va. Judge Advances Most Claims In Stelara Antitrust Case
• Trump Executive Order Calls Fentanyl A 'WMD'
• The Most Important Healthcare And Life Science Deals Of 2025
• A Uniform Federal Rule Would Curb Gen AI Missteps In Court
• Trends That Shaped Healthcare Dealmaking In 2025
• Merck Sued Over Time Rounding, OT Averaging At NC Plant
• Jury Says Magnolia Medical Is Owed $1.6M After Patent Trial
• 5 Big Litigation Developments Out Of Georgia In 2025
• Another Dechert IP Atty Leaves, This Time For Morgan Lewis
• Medical Device Maker Zynex Hits Ch. 11 With Sale Plans
• Smartwatch Giants Sued Over Fall Detection Patents
• States Fight Sandoz Bid To Argue Duplication In Generics Row
• DOJ Raises Accreditation Concerns In Vet School Case
• Ohio Gov. To Designate Synthetic Kratom Extract Illegal Drug
• Formula Suits An 'Undue Burden' On Cook County, Panel Says
• USPTO Replaces Denver Office With Center In Montana
• Cencora Pays $5B For Majority Stake Of OneOncology
• Connecticut 'Likely' To Settle Generic Drug Price Cap Dispute
• Fed. Circ. Won't Revive Bard Patents In AngioDynamics Row
• Blank Rome Hires Baker McKenzie Litigator In DC
• The Top Patent Decisions Of 2025
• Riding The Changing Winds For AI Innovations At The USPTO
• The Law Firm Merger Diaries: Integrating Practice Groups
• PTAB Creates New Prehearing Conference For AIA Reviews
• High Court Won't Review Doctor 'Upcoding' Acquittal Decision
• Supreme Court Declines Cannabis Ban Review
• Supreme Court Turns Down Entresto Patent Fight
• McDermott-Led Sobi To Buy US Gout Specialist For $1.5B
• 1st Circ. OKs Barring Medicaid Planned Parenthood Coverage
• Ore. Justices Rule Docs Can Be Liable For Nonpatient Deaths
• Squires Institutes 7 AIA Reviews, Denies 12 Other Petitions
• CooperSurgical Escapes Repeat Filshie Clip Claims In Conn.
• Supreme Court Term Limits Would Carry Hidden Risk
• Next Steps For Orgs. Amid Updated OpenAI Usage Policies
• Mississippi Litigator Joins Butler Snow From Adams & Reese
• Fed. Circ. Says PTAB Was Right To Ax Tracking Patent Claims
• Higgs Fletcher Forms White Collar, Regs Enforcement Team
• LA Bellwether Jury To Decide If J&J Hid Talc Risk For Decades
• DC Circ. Oversees FDA Fight Over Generic IBS Drug
• Tracking Challenges To USPTO's Discretion Policy
• Pharmacies Battle For Coverage Of Opioid Lawsuit Claims
• NC County Sues DuPont, 3M, Tyco Over PFAS Contamination
• Elevance Health Adds Former Pfizer GC To Its Board
• Sidley Guides Diagnostic Imaging Firm Lumexa's $463M IPO
• 6th Circ. Panel Shows No Leanings On PBM Jurisdiction Fight
• 4 Firms Guide As Arcline Exits Medical Tech Co. In $685M Deal
• Knitting Makes Me A Better Lawyer
• How 11th Circ.'s Qui Tam Review Could Affect FCA Litigation
• Diagnostic Co. Agrees To Oversight Reforms In Derivative Suit
• Teva Pulls 200 Patents From Orange Book Amid FTC Probe
• Apple Tells Fed. Circ. ITC Move Boosts Watch Case Appeal
• The Biz Court Digest: Welcome To Miami
• Med Delivery Co. Fired Workers For Pay Complaints, Suit Says
• Akerman Hires DOJ Civil Division Lawyer For Healthcare Team
• Identifying And Resolving Conflicts Among Class Members
• VC Apple Tree Hits Ch. 11 After Row With Russian Billionaire
• Weil, Reed Smith Build WTW's Newfront Buy For Up To $1.3B
• Generic-Drug Group Backs House Bill On Skinny Labels
• Conn. Seems Open To Limits On Drug Price Cap Enforcement
• NJ Drugmaker, Chubb Settle $6.5M Defense Costs Suit
• Adapting To A Plaintiff-Side Mindset For Patent Monetization
• Expert Invoices Discoverable In J&J Talc MDL, Judge Says
• Mistrial Declared In Fla. Opioid Case Against Pharmacies
• Hagens Berman's Novel DOJ Referral May Have Chilling Effect
• Medical Appliance Co. Seeks Coverage For SEC Investigation
• Cooley Adds 30-Person Life Sciences IP Team From Dechert
• Teleflex To Divest Multiple Units In Deals Topping $2B
• AI Evidence Rule Tweaks Encourage Judicial Guardrails
• Inari Loses Fed. Circ. Bid To Save Corn Seed Patent Review
• 1st Circ. Keeps Planned Parenthood Funding Ban In Place
• What To Do When Jurors Don't 'Trust The Science'
• 4th Circ. Backs EIDP In Dispute Over Annuity Reductions
• Chancery Blocks Opt-Out In $32M Emisphere Settlement
• 4 Firms Lead $1.51B TC Transcontinental Packaging Deal
• The Law Firm Merger Diaries: Getting The Message Across
• Hi-Tech Pharma, CEO Want New Trial In Feds' Fraud Case
• Catching Up With Delaware's Chancery Court
• Horizontal Stare Decisis Should Not Be Casually Discarded
• High Court Wants Feds' Input On Health Workers' Vax Fight
• Juror Who Alleged Misconduct Dismissed From Opioid Trial
• SG Urges Justices To Hear Hikma's 'Skinny Label' Patent Case
• Judge Won't Lift Stay On Hopewell Drug Launch
• ITC Bans Infringing Drill Bit Imports After Fed. Circ. Remand
• Cancer Detection Biz Going Public Via $1.1B SPAC Merger
• Pharma Co. Says Ex-Staff Used Secrets To Compete
• Medline Accused In Chancery Of Withholding $10M Earnout
• Mass Tort Firms Targeted Over Benicar MDL Fees In NJ Suits
• CDC Panel Ends Recommendation Of Hepatitis B Shot At Birth
• 10 Commandments For Agentic AI Tools In The Legal Industry
• Wheeling & Appealing: The Latest Must-Know Appellate Action
• Class Cert. Denied In Splenda False Ad Suit
• 11th Circ. Blocks Fla. City's Abortion Clinic Buffer Zone Law
• Squires Clarifies Points On Patent Eligibility Declarations
• Fed. Circ. In Oct.: Spotlight On Wording Beyond Patent Claims
• CDC Vaccine Committee Punts Hepatitis B Vote Again
• Fla. High Court Backs University Control Over Nonprofit
• Geico Claims Cos. Ran $2.7M Medical Device Billing Scheme
• New Drug Ad Regs Could Lead To A Less Informed Public
• Medical Device Co. Faces Investor Suit Over IV Pump Issues
• Pharma Cos. Denied Early Win In States' Price-Fixing Suit
• Judge Nixes Hagens Berman's Recusal Bid After DOJ Referral
• Vivimed To Pay $1.9M To End Losartan Economic Loss Claims
• Preaching Makes Me A Better Lawyer
• USPTO Gets Earful On Plan To Restrict Patent Reviews
• Pharmacies Want Opioid Mistrial As Deliberations Stretch On
• Pharma Co. Exec Faces $125K SEC Judgment In Fraud Case
• NuVasive Urges Del. Justices To Revive Officer Conflict Suit
• Kevin O'Leary, Company Execs Fight Patent Forgery Suit
• 'Dr. P.' Gets 2.5 Years For Selling Ketamine To Matthew Perry
• AT&T Sues Generic Drug Manufacturers, Alleging Price-Fixing
• Novartis, Swiss Marketer Want Out Of Trade Secrets Suit
• A Look At Middlemen Fees In 340B Drug Discount Program
• Fed. Circ. Backs Axed Claims In Heart Rate Monitor Patent
• How Large Patent Damages Awards Actually Play Out
• Judge To OK $16.5M 23andMe Insurer Buyback Deal In Ch. 11
• AGs Say Sun, Taro Settlement Mustn't Touch State Claims
• 7 Pension Funds Picked To Lead Neogen Investor Class
• WilmerHale Hires BNP Paribas Director In Boston
• Law School's Missed Lessons: Practicing Client-Led Litigation
• Squires Institutes First PTAB Challenges Since Taking Over
• Judge Blocks Planned Parenthood Funding Cut In 22 States
• 9th Circ. Mulls Pharma Exec's Use Of Forced Arbitration Law
• U Of Colo. To Pay $10M In Religious Bias Suit Over Vax Policy
• Navigating 2025's Post-Grant Proceeding Shakeups
• Monthly Merger Review Snapshot
• Defamation Litigation Roundup: FDA, Lively, Alexander Bros.
• UK Importer Must Pay Tax On PPE, Court Affirms
• Under New Chair, Fed. Vax Panel To Redo Hep B Vote
• Fed. Circ. Erases $41.8M Verdict Over Seagen Cancer Drug IP
• Hagens Berman Referred To DOJ For Alleged Misconduct
• MVP: Williams & Connolly's David M. Krinsky
• CVS Will Pay $37.8M To Settle Insulin Pen Overbilling Claims
• Bristol-Myers Must Face Trimmed $6.7B Celgene Investor Suit
• Hospitals Slam HHS' Move From Drug Discounts To Rebates
• 1st Circ. Tosses Omni's Medicare Fraud Suit Over UTI Tests
• Merck Wants Fed. Circ. Redo On Decision Backing Axed IP
• 2nd Circ. Backs Anti-Abortion Groups' Free Speech Rights
• UK To Raise Pharma Spending For US Tariff Protection
• FDA Withdraws Proposed Talc Cosmetics Testing Rule
• The Law Firm Merger Diaries: How To Build On Cultural Fit
• Latisse Ruling's Lessons On Avoiding Chemical Patent Pitfalls
• Mich. Law Firm's Misrepresentation Voids Policy, Insurer Says
• What MDL Judges Can Get Done With A New Civil Rule
• Squire Patton Brings On DLA Piper Patent Litigator In SF
• MVP: Sidley's Sally Wagner Partin
• Meet The Attys Arguing Gov't Subpoena Power At High Court
• Catching Up With Delaware's Chancery Court